联环药业：控股子公司获得《药品补充申请批准通知书》

Core Viewpoint - The announcement indicates that the approval for the marketing authorization holder of Ursodeoxycholic Acid Capsules has been transferred from Hunan Chunjian Pharmaceutical Technology Co., Ltd. to Changle Pharmaceutical, a subsidiary of Lianhuan Pharmaceutical [1] Company Summary - Lianhuan Pharmaceutical's subsidiary, Changle Pharmaceutical, has received approval from the National Medical Products Administration for the marketing authorization of Ursodeoxycholic Acid Capsules [1] - The approval signifies a strategic shift in the ownership of the marketing rights for the drug, which may impact the company's market positioning and revenue potential [1]